Cargando…
A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study
BACKGROUND: To explore the postoperative prognosis of esophageal squamous cell carcinoma (ESCC) patients with stage IB/IIA, using a prognostic score (PS). METHODS: Stage IB/IIA ESCC patients who underwent esophagectomy from 1999 to 2010 were included. We retrospectively recruited 153 patients and ex...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876804/ https://www.ncbi.nlm.nih.gov/pubmed/33568088 http://dx.doi.org/10.1186/s12876-021-01636-5 |
_version_ | 1783650041490046976 |
---|---|
author | Wu, Lei-Lei Ma, Qi-Long Huang, Wei Liu, Xuan Qiu, Li-Hong Lin, Peng Long, Hao Zhang, Lan-Jun Ma, Guo-Wei |
author_facet | Wu, Lei-Lei Ma, Qi-Long Huang, Wei Liu, Xuan Qiu, Li-Hong Lin, Peng Long, Hao Zhang, Lan-Jun Ma, Guo-Wei |
author_sort | Wu, Lei-Lei |
collection | PubMed |
description | BACKGROUND: To explore the postoperative prognosis of esophageal squamous cell carcinoma (ESCC) patients with stage IB/IIA, using a prognostic score (PS). METHODS: Stage IB/IIA ESCC patients who underwent esophagectomy from 1999 to 2010 were included. We retrospectively recruited 153 patients and extracted their medical records. Moreover, we analyzed the programmed death ligand-1 (PD-L1) expression of their paraffin tissue. The cohort were randomly divided into a training group (N = 123) and a validation group (N = 30). We selected overall survival (OS) as observed endpoint. Prognostic factors with a multivariable two-sided P < 0.05 met standard of covariate inclusion. RESULTS: Univariable and multivariable analyses identified pTNM stage, the number of lymph nodes (NLNs) and PD-L1 expression as independent OS predictors. Primary prognostic score which comprised above three covariates adversely related with OS in two cohorts. PS discrimination of OS was comparable between the training and internal validation cohorts (C-index = 0.774 and 0.801, respectively). In addition, the PS system had an advantage over pTNM stage in the identification of high-risk patients (C-index = 0.774 vs. C-index = 0.570, P < 0.001). Based on PS cutoff, training and validation datasets generated low-risk and high-risk groups with different OS. Our three-factor PS predicted OS (low-risk subgroup vs. high-risk subgroup 60-month OS, 74% vs. 23% for training cohort and 83% vs. 45% for validation cohort). CONCLUSION: Our study suggested a PS for significant clinical stratification of IB/IIA ESCC to screen out subgroups with poor prognosis. |
format | Online Article Text |
id | pubmed-7876804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78768042021-02-11 A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study Wu, Lei-Lei Ma, Qi-Long Huang, Wei Liu, Xuan Qiu, Li-Hong Lin, Peng Long, Hao Zhang, Lan-Jun Ma, Guo-Wei BMC Gastroenterol Research Article BACKGROUND: To explore the postoperative prognosis of esophageal squamous cell carcinoma (ESCC) patients with stage IB/IIA, using a prognostic score (PS). METHODS: Stage IB/IIA ESCC patients who underwent esophagectomy from 1999 to 2010 were included. We retrospectively recruited 153 patients and extracted their medical records. Moreover, we analyzed the programmed death ligand-1 (PD-L1) expression of their paraffin tissue. The cohort were randomly divided into a training group (N = 123) and a validation group (N = 30). We selected overall survival (OS) as observed endpoint. Prognostic factors with a multivariable two-sided P < 0.05 met standard of covariate inclusion. RESULTS: Univariable and multivariable analyses identified pTNM stage, the number of lymph nodes (NLNs) and PD-L1 expression as independent OS predictors. Primary prognostic score which comprised above three covariates adversely related with OS in two cohorts. PS discrimination of OS was comparable between the training and internal validation cohorts (C-index = 0.774 and 0.801, respectively). In addition, the PS system had an advantage over pTNM stage in the identification of high-risk patients (C-index = 0.774 vs. C-index = 0.570, P < 0.001). Based on PS cutoff, training and validation datasets generated low-risk and high-risk groups with different OS. Our three-factor PS predicted OS (low-risk subgroup vs. high-risk subgroup 60-month OS, 74% vs. 23% for training cohort and 83% vs. 45% for validation cohort). CONCLUSION: Our study suggested a PS for significant clinical stratification of IB/IIA ESCC to screen out subgroups with poor prognosis. BioMed Central 2021-02-10 /pmc/articles/PMC7876804/ /pubmed/33568088 http://dx.doi.org/10.1186/s12876-021-01636-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wu, Lei-Lei Ma, Qi-Long Huang, Wei Liu, Xuan Qiu, Li-Hong Lin, Peng Long, Hao Zhang, Lan-Jun Ma, Guo-Wei A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title | A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title_full | A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title_fullStr | A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title_full_unstemmed | A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title_short | A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study |
title_sort | prognostic model for stratification of stage ib/iia esophageal squamous cell carcinoma: a retrospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876804/ https://www.ncbi.nlm.nih.gov/pubmed/33568088 http://dx.doi.org/10.1186/s12876-021-01636-5 |
work_keys_str_mv | AT wuleilei aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT maqilong aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT huangwei aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT liuxuan aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT qiulihong aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT linpeng aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT longhao aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT zhanglanjun aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT maguowei aprognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT wuleilei prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT maqilong prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT huangwei prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT liuxuan prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT qiulihong prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT linpeng prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT longhao prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT zhanglanjun prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy AT maguowei prognosticmodelforstratificationofstageibiiaesophagealsquamouscellcarcinomaaretrospectivestudy |